Bio-Rad Laboratories, Inc. (BIO) 股票分析

公司概述

Bio-Rad Laboratories, Inc. operates as a specialized developer, manufacturer, and distributor of life science research and clinical diagnostic products, serving markets across the United States, Europe, Asia, Canada, Latin America, and internationally. The company functions within the Healthcare sector, specifically the Medical Devices industry, which involves the creation of tools essential for laboratory analysis, disease detection, and biological research. This entity commands a significant market capitalization of $7.49 billion and reported annual revenue of $2.58 billion, supported by a workforce of 7,450 employees. These valuation and revenue figures indicate that Bio-Rad Laboratories maintains a substantial market footprint, positioning it as a major player capable of sustaining operations and R&D investments across multiple global regions.

财务健康

Bio-Rad Laboratories generated $2.58 billion in revenue over the trailing twelve months, resulting in a net income of $759.90 million and an EBITDA of $431.60 million. The substantial gap between the $2.58 billion revenue and the $759.90 million net income reveals a cost structure where operating expenses, taxes, and interest consume a significant portion of gross sales, though the high gross margin mitigates this pressure. The company produced $256.55 million in free cash flow, which provides a critical buffer for financial flexibility, enabling debt repayment or capital allocation without relying on external financing. Profitability is underscored by three distinct margins: a gross margin of 52.0%, an operating margin of 8.9%, and a profit margin of 29.4%, indicating strong pricing power relative to the cost of goods sold despite operational overheads. Regarding leverage, the company holds $1.54 billion in cash against $1.38 billion in debt, with a debt-to-equity ratio of 18.58, suggesting a balance sheet that carries significant leverage relative to its equity base. Liquidity is robust, evidenced by a current ratio of 5.62, which signifies that current assets vastly exceed current liabilities, ensuring the ability to meet short-term obligations. Finally, the Return on Equity stands at 10.8% while Return on Assets is 1.7%, revealing that management generates higher returns specifically on shareholders' equity compared to the total asset base, highlighting the impact of the company's leveraged capital structure on equity performance.

估值评估

The trailing twelve-month P/E ratio is 9.96, while the forward P/E is 24.45, implying that the market expects earnings to grow significantly in the future to justify the higher multiple required for forward-looking valuations. The price-to-book ratio is 1.00, indicating that the stock currently trades at par value with no market premium or discount relative to its tangible book value. Alternative valuation metrics such as the price-to-sales ratio of 2.90 and an EV/EBITDA of 16.99 suggest the company is priced at a level that reflects its revenue generation efficiency and enterprise value relative to earnings before interest, taxes, depreciation, and amortization. Price action over the past year has oscillated between a 52-week high of $343.12 and a 52-week low of $211.43, meaning the current price sits at a specific point within this historical trading range that reflects recent market sentiment. The beta value of 1.16 indicates that the stock's price volatility is slightly higher than the broader market, suggesting it tends to move with greater intensity than the overall index during periods of market fluctuation.

Growth & Income

Revenue growth over the last year stands at 3.9%, while earnings growth is listed as N/A, indicating that specific year-over-year earnings expansion metrics are not currently disclosed in the available data. The absence of a specific earnings growth figure alongside the 3.9% revenue growth suggests that the company is expanding its top line, though the precise relationship between revenue and earnings expansion requires direct earnings data to fully quantify. As a non-dividend payer, Bio-Rad Laboratories does not distribute cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which implies the company retains all earnings for reinvestment into research, development, or balance sheet strengthening rather than paying dividends. The overall growth and income profile is characterized by steady single-digit revenue expansion and a complete retention of cash flows, focusing on internal capital generation rather than income distribution to investors.